Company: RGBP
Filing Date: 2025-10-03
Form Type: 8-K
Source: 0001493152-25-016767
Chunk: 0

Company: Regen BioPharma Inc
Filing Date: 2025-10-03
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry into a Material Definitive Agreement.

On
October 2, 2025 Regen Biopharma, Inc. (the “ Company”) entered into a consulting agreement
with Dr. Harry Lander (“ Lander Agreement”). Under the terms and conditions of the Lander Agreement Harry Lander will assist
the Company in regard to a planned Phase I Clinical Trial of HemaXellerate. The term of the Lander Agreement is from October 3, 2025
to the earlier of October 3, 2028 or successful completion of the planned Phase I Clinical Trial of HemaXellerate (“ Consulting
Period”).

As
consideration for services to be rendered pursuant to this Agreement Dr. Lander was paid twenty million newly issued common shares of
the Company (“ Compensation Shares”) subject to a vesting schedule.

The
Compensation Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Lander (“ Transfer
Restriction”) except as follows:

All
Compensation Shares shall vest upon successful completion of planned Phase I Clinical Trial of HemaXellerate, such Clinical Trial having
been conducted with the assistance of the Consultant pursuant to the terms and conditions of this Agreement.

In
the event of termination of the Consulting Period any Compensation Shares still subject to Transfer Restrictions shall be forfeited by
the Consultant and ownership of those Compensation Shares shall be transferred back to the Company.

The
foregoing description of the abovementioned Lander Agreement is not complete and is qualified in its entirety by reference to the text
of the abovementioned Lander Agreement which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this
Item 1.01 by reference.

On
October 2, 2025 the Company entered into an agreement with David Koos, the Company’s Chairman
and Chief Executive Officer (“ Koos Agreement”). Pursuant to the Koos Agreement David Koos was paid twenty million newly issued
common shares of the Company (“ Koos Compensation Shares”) subject to a vesting schedule. The Company has issued these shares
to Davis Koos as consideration for services to be rendered by Koos in connection with a planned Phase I Clinical Trial of HemaXellerate.

The
Koos Compensation Shares may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by David Koos (“
Transfer Restriction”) except as follows:

All